Response of brain metastasis from lung cancer patients to an oral nutraceutical product containing silibinin

Despite multimodal treatment approaches, the prognosis of brain metastases (BM) from non-small cell lung cancer (NSCLC) remains poor. Untreated patients with BM have a median survival of about 1 month, with almost all patients dying from neurological causes. We herein present the first report descri...

Descripción completa

Detalles Bibliográficos
Autores principales: Bosch-Barrera, Joaquim, Sais, Elia, Cañete, Noemí, Marruecos, Jordi, Cuyàs, Elisabet, Izquierdo, Angel, Porta, Rut, Haro, Manel, Brunet, Joan, Pedraza, Salvador, Menendez, Javier A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5077992/
https://www.ncbi.nlm.nih.gov/pubmed/26959886
http://dx.doi.org/10.18632/oncotarget.7900

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5077992/
https://www.ncbi.nlm.nih.gov/pubmed/26959886
http://dx.doi.org/10.18632/oncotarget.7900

Ejemplares similares